Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
16
×
life sciences
national blog main
national top stories
san francisco blog main
biotech
deals
new york blog main
san francisco top stories
boston
new york top stories
clinical trials
gene therapy
national
san diego blog main
san diego top stories
alnylam pharmaceuticals
crispr
gene editing
hemophilia
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
editas medicine
fda
indiana blog main
indiana top stories
pfizer
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
spark therapeutics
startups
texas blog main
texas top stories
vc
wisconsin blog main
What
gene
16
×
therapy
medicine
bio
drug
editing
crispr
medicines
roundup
editas
fda
race
rna
approval
aren’t
cas
cells
cutting
deal
disease
edge
experimental
genetic
help
human
interference
long
market
moves
past
patients
prices
protein
research
roche
science
therapeutics
treatment
years
abbvie
Language
unset
Current search:
gene
×
" boston top stories "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
5 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M